Results 11 to 20 of about 14,484 (178)

Knowledge, Attitude, and Practices of Moroccan Retail Pharmacists towards Veterinary Medicines

Advances in Pharmacological and Pharmaceutical Sciences, 2022
This is the first study conducted in Morocco to assess knowledge, attitude, and practices of retail pharmacists regarding veterinary medicines. It is a cross-sectional study.
Zeinab Snoussi, Samir Ahid
doaj   +1 more source

Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis

Frontiers in Pharmacology, 2022
Objective: After Gemstone-302 was published in Lancet in January 2022, seven PD-(L)1 inhibitors launched or about to be launched in China, but there are no head-to-head RCTs reporting the comparative efficacy for squamous non-small cell lung cancer (sq ...
Mingye Zhao, Mingye Zhao, Taihang Shao, Taihang Shao, Yinan Ren, Yinan Ren, Caicun Zhou, Wenxi Tang, Wenxi Tang   +8 more
doaj   +1 more source

A survey of pharmacists' knowledge, attitudes and barriers in pharmaceutical care concept in Poland

BMC Medical Education, 2021
Background The major goals of pharmaceutical care (PC) are to improve the patient’s quality of life and ensure safety of pharmacotherapy. Inclusion of a pharmacist in the multidisciplinary team caring for the patient and integration of state-of-the-art ...
Dorota Kopciuch, Anna Paczkowska, Tomasz Zaprutko, Piotr Ratajczak, Elżbieta Nowakowska, Krzysztof Kus   +5 more
doaj   +1 more source

Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method

Cost Effectiveness and Resource Allocation, 2023
Objectives Monetizing health has sparked controversy and has implications for pricing strategies of emerging health technologies. Medical insurance payers typically set up thresholds for quality-adjusted life years (QALY) gains based on health ...
Qian Peng, Yue Yin, Min Liang, Mingye Zhao, Taihang Shao, Yaqian Tang, Zhiqing Mei, Hao Li, Wenxi Tang   +8 more
doaj   +1 more source

Pharmacoeconomics

YAKUGAKU ZASSHI, 2003
AbstractFor Abstract see ChemInform Abstract in Full Text.
openaire   +4 more sources

Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis

Frontiers in Pharmacology, 2023
Background and objective: Non-small cell lung cancer (NSCLC) is one of the most malignant cancer types that causes substantial economic burden in China.
Xi Chen, Xi Chen, Mingye Zhao, Mingye Zhao, Lei Tian, Lei Tian   +5 more
doaj   +1 more source

Instant velocity and consistency of emitted cloud change by the different levels of canister filling with Metered Dose Inhalers (MDIs), but not with Soft Mist Inhalers (SMIs): a bench study

Multidisciplinary Respiratory Medicine, 2017
Background Inhalation is the preferred route for respiratory drug delivery, but several factors contribute to the variability of the respirable dose fraction. Instant velocity and the dynamic characteristics of the droplet cloud represent crucial factors.
Roberto W. Dal Negro, Pietro Longo, Orestepaolo Villanis Ziani, Luca Bonadiman, Paola Turco   +4 more
doaj   +1 more source

Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model

Frontiers in Public Health, 2023
BackgroundA total of 11 treatment sequences for advanced wild-type squamous non-small cell lung cancer are recommended by Chinese Society of Clinical Oncology Guidelines, consisting of seven first-line and three second-line treatments.
Mingye Zhao, Mingye Zhao, Taihang Shao, Taihang Shao, Zhuoyuan Chi, Zhuoyuan Chi, Wenxi Tang, Wenxi Tang   +7 more
doaj   +1 more source

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis

Arthritis Research & Therapy, 2017
Background Biologic disease-modifying antirheumatic drugs (DMARDs) are increasingly used for rheumatoid arthritis (RA) treatment. However, little is known based on contemporary data about the factors associated with DMARDs and patterns of use of biologic
Yinzhu Jin, Rishi J. Desai, Jun Liu, Nam-Kyong Choi, Seoyoung C. Kim   +4 more
doaj   +1 more source

Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare setting

Journal of Market Access & Health Policy, 2023
Background The evidence base of tisagenlecleucel is uncertain.Objective To evaluate the cost-effectiveness of tisagenlecleucel. To conduct expected value of perfect information (EVPI) and partial EVPI (EVPPI) analyses.Study Design A three-state ...
Niamh Carey, Joy Leahy, Lea Trela-Larsen, Laura Mc Cullagh, Michael Barry   +4 more
doaj   +1 more source